leisure time -WSS

leisure time

author：entertainment 2025-08-12 09:09:16 - browse：9

Adam's take main illustration — Molly Ferguson/STAT

Roivant Sciences’ Matt Gline might be this year’s best biopharma CEO, and other thoughts about Monday’s blockbuster deal with Roche — like, why the heck did Roivant’s stock trade down?

Gline created $5 billion from $50 million — in less than one year.Regular readers know that every December, I choose a best biopharma CEO. It’s a subjective award, but deal-making acumen, management skills, and delivering shareholder value are important measuring sticks. It’s still too early to call this year’s contest, but Gline is a front-runner.

Last December, Roivant essentially acquired an experimental treatment for inflammatory bowel disease called RVT-3101 from Pfizer for $45 million and then spent another $5 million to position the drug for future Phase 3 studies. Less than a year later, Roivant flipped the drug to Roche for at least $7.1 billion.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： FTC sues over Novant Health acquisition of two N.C. hospitals

focus

hotspot

WSS

Too many hospitalized Covid

Lilly to acquire Dermira for $1.1 billion, adding eczema drug to its pipeline

White House pharmacy plagued with problems, investigation finds

Resistance to opioid

Readout Newsletter: Replicate, Biogen's Leqembi, and Humira

Readout Newsletter: Amylyx, Aurinia, and IQVIA

knowledge

leisure time

focus

Dobbs anniversary: the lost opportunity of abortion as health care

The Affordable Care Act has saved billions in health care costs

Tori Bowie and the unacceptable rates of Black maternal death

Latigo launches with $135 million for Vertex

Drug repurposing or repositioning? The language matters

Congress must protect the remaining independent doctors

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

New clues to why women have higher risk of autoimmune disorders

Malaria cases in Florida and Texas: Here’s what you need to know

Readout Newsletter: The latest on Novavax, Merck, Bluebird

entertainment

Medicare Advantage insurers face 0.2% cut to 2025 payments

AMAs digital advisors table RPM coding reform proposal, again

Having children helps parents live longer, especially after age 80

ACIP vaccine advisory panel sees its vacancies filled

Vertex non

Readout Newsletter: Amylyx, Aurinia, and IQVIA

focus

Wikipedia

hotspot

leisure time